OPTIMISE-CKD drug utilization - OPTIMISE-CKD

Study identifier:D169AR00015

ClinicalTrials.gov identifier:NCT05932901

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A multinational, observational, secondary data study describing management and treatment with dapagliflozin in routine clinical practice among patients with chronic kidney disease

Medical condition

Chronic Kidney Disease

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

2682052

Study type

Observational

Age

18 Years - 130 Years

Date

Study Start Date: 04 May 2022
Primary Completion Date: 28 Sept 2023
Study Completion Date: 28 Sept 2023

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2023 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria